| 2.92 -0.01 (-0.34%) | 04-21 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.92  |
1-year : | 4.59 |
| Resists | First : | 3.35 |
Second : | 3.93 |
| Pivot price | 2.75 |
|||
| Supports | First : | 2.42 | Second : | 2.01 |
| MAs | MA(5) : | 2.79 |
MA(20) : | 2.87 |
| MA(100) : | 6.17 |
MA(250) : | 10.84 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 41.5 |
D(3) : | 33.9 |
| RSI | RSI(14): 42.5 |
|||
| 52-week | High : | 24.89 | Low : | 2.42 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ INBS ] has closed below upper band by 32.6%. Bollinger Bands are 81.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 38 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.16 - 3.18 | 3.18 - 3.19 |
| Low: | 2.73 - 2.75 | 2.75 - 2.76 |
| Close: | 2.89 - 2.92 | 2.92 - 2.94 |
Intelligent Bio Solutions Inc., a life sciences company, developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
Mon, 20 Apr 2026
Intelligent Bio Solutions (INBS) Launches Study to Enhance Drug Screening Speed - GuruFocus
Mon, 20 Apr 2026
Fingerprint drug test aims for under-3-minute roadside results - Stock Titan
Mon, 20 Apr 2026
Intelligent Bio Solutions Updates Investor Presentation and Share Count - TipRanks
Mon, 20 Apr 2026
Intelligent Bio Solutions (NASDAQ: INBS) posts new investor deck and share update - Stock Titan
Fri, 17 Apr 2026
Intelligent Bio Solutions (INBS) Enhances Security Ahead of FDA Submission - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 2 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 4.2 (%) |
| Held by Institutions | 0.2 (%) |
| Shares Short | 45 (K) |
| Shares Short P.Month | 94 (K) |
| EPS | -14.45 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 8.96 |
| Profit Margin | 0 % |
| Operating Margin | -290.9 % |
| Return on Assets (ttm) | -51.2 % |
| Return on Equity (ttm) | -150.2 % |
| Qtrly Rev. Growth | 47.5 % |
| Gross Profit (p.s.) | 0.82 |
| Sales Per Share | 1.78 |
| EBITDA (p.s.) | -4.93 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | -15 (M) |
| PE Ratio | -0.21 |
| PEG Ratio | 0 |
| Price to Book value | 0.32 |
| Price to Sales | 1.63 |
| Price to Cash Flow | -0.63 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|